Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

BioNexus Gene Lab (BGLC) EPS (Weighted Average and Diluted) (2023 - 2025)

BioNexus Gene Lab's EPS (Weighted Average and Diluted) history spans 3 years, with the latest figure at -$0.4 for Q3 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$0.4 for Q3 2025, up 47.26% from a year ago — trailing twelve months through Sep 2025 was -$0.16 (up 68.56% YoY), and the annual figure for FY2024 was -$0.09, up 45.78%.
  • EPS (Weighted Average and Diluted) for Q3 2025 was -$0.4 at BioNexus Gene Lab, down from -$0.34 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.61 in Q4 2024 to a low of -$0.75 in Q3 2024.
  • The 3-year median for EPS (Weighted Average and Diluted) is -$0.02 (2024), against an average of -$0.1.
  • The sharpest move saw EPS (Weighted Average and Diluted) surged 2673.01% in 2024, then plummeted 483.33% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at $0.02 in 2023, then surged by 2673.01% to $0.61 in 2024, then tumbled by 164.33% to -$0.4 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.4, -$0.34, and -$0.04 for Q3 2025, Q2 2025, and Q1 2025 respectively.